BiVictriX Therapeutics Plc is a biotechnology company, which engages in the research and experimental development of pharmaceutical products. The firm also focuses on generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. The company was founded by Peter Jackson and Tiffany Thorn in 2016 and is headquartered in Cheshire, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company